Luokat: Kaikki - treatment - drugs

jonka Suwan Kim 2 vuotta sitten

128

Melanoma

The text discusses various treatment options for melanoma, focusing on different drugs and their specific approvals. PD-1 inhibitors like Nivolumab and Pembrolizumab are highlighted for their roles in treating resectable, unresectable, and metastatic melanoma.

Melanoma

Melanoma

Treatment Options

Adjuvant therapy
Metastatic - extend overall survival

Combo BRAF/MEK inhibitor

Nivolumab + Ipilimumab

recommended first line for metastatic melanoma regardless of PDL1 expression

Pembrolizumab

Non-metastatic - decrease recurrence time

Topical imiquimod or radiation if exclusion

Dabrafenib/trametinib (BRAF V600)

Ipilimumab

Surgery
Primary treatment

Drugs

PD-1 inhibitors
pembrolizumab

approved as single agent for resectable or metastatic melanoma

Nivolumab

approved for adjuvant treatment after complete resection

approved for single agent and in combo w/ ipilmumab for unresectable or metastatic melanoma

CTLA4 inhibitors
Ipilmumab

Tox rash diarrhea liver tox hypophysitis

manage diarrhea and livertox w/ high dose steroids infliximab second line for diarrhea mycophendlate second line for liver tox

infliximab contraindicated in liver disease

has the highest tox among checkpoint inhibitors

BRAF/MEK inhibitors
tox skin oddities pyrexia diarrhea eleved CK and LFTs
trametinib + cobimetinib
Dabrafenib + vemurafenib

also approved for adjuvant therapy for pt w/ mutation w/ lymph node involvement following complete resection

Approved for unresectable or metastatic melanoma w/ BRAF V600 mutations
IL-2
tox capillary leak syndrome constitutional symptoms infections N/V chills
Steroids are CONTRAINDICATED due to risk of infections and GI side effects
administed in ICU
approved for metastatic melanoma
IFN alpha-2b
Avoid in autoimmune chronically immunosuppressed liver disease severe neuropsychiatric diseases life-treat infection
tox granulocytopenia increased LFTs flu symptoms depression anorexia fatigue
approved for stage III high risk

Staging

Metastatic (Stage IV)
Systemic therapy for stage IV
Regional (Stage III)
Adjuvant therapy for stages IIB-IIIC
Localized (Stage I-II)
Surgery for stages 0-IIA